Market Overview

Teva Holders Shrug at FDA Approval of Generic-Version of Novartis' TOBI in US

Related TEVA
Mid-Morning Market Update: Markets Edge Lower; Morgan Stanley Beats Q4 Estimates
Teva's Cost-Cutting Plan Nets A Mizuho Upgrade
U.S. Justice Department may seek damages from generic drugmakers for price-fixing (Seeking Alpha)
Related NVS
Attention Biotech Investors: Brace For These January PDUFA Events
The Companies That Led 2017's Biotech Rally
3 Things In Biotech You Should Learn Today: January 19, 2018 (Seeking Alpha)

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces today that the U.S. Food and Drug Administration has granted approval of the generic equivalent to TOBI^® (Tobramycin Inhalation Solution USP) in the United States. Pursuant to an agreement with Novartis (NYSE: NVS) on this product, Teva expects to launch this product in late November. Marketed by Novartis, TOBI^® had annual sales of approximately $350 million in the United States, according to IMS data as of June 30, 2013.

Posted-In: News FDA


Related Articles (TEVA + NVS)

View Comments and Join the Discussion!